Compare NLY & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NLY | FMS |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Misc Health and Biotechnology Services |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 14.1B |
| IPO Year | 1997 | 1996 |
| Metric | NLY | FMS |
|---|---|---|
| Price | $22.86 | $23.27 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 9 | 2 |
| Target Price | $21.63 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 6.7M | 482.1K |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | ★ 12.24% | 2.45% |
| EPS Growth | N/A | ★ 8.62 |
| EPS | 2.19 | ★ 2.86 |
| Revenue | $1,748,174,000.00 | ★ $23,046,819,198.00 |
| Revenue This Year | $358.71 | $2.12 |
| Revenue Next Year | $8.02 | $2.92 |
| P/E Ratio | ★ $10.42 | $15.86 |
| Revenue Growth | ★ 275.23 | 2.10 |
| 52 Week Low | $16.60 | $22.05 |
| 52 Week High | $22.98 | $30.46 |
| Indicator | NLY | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 70.52 | 37.10 |
| Support Level | $22.66 | $22.51 |
| Resistance Level | $22.98 | $24.20 |
| Average True Range (ATR) | 0.29 | 0.30 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 92.11 | 45.27 |
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are; the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.